Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADHD SWITCH: Slow vs Fast Transition to Atomoxetine
NCT00760747Phase 4Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2008
- Primary completion
- Aug 2010
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 4 trial of atomoxetine in attention deficit hyperactivity disorder (ADHD), sponsored by Eli Lilly and Company. Started Sep 2008; status: completed.
02
Drugs
atomoxetine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT00760747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00760747.